SOURCE: Bioniche Life Sciences, Inc.

Bioniche Life Sciences, Inc.

September 17, 2014 10:19 ET

Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical

NEW YORK, NY--(Marketwired - Sep 17, 2014) - Bioniche Life Sciences, Inc. (PINKSHEETS: BNHLF) (TSX: BNC), a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market, has been featured in a new article that highlights this busy but "under the radar" company with quite a story to tell. Sujan Lahiri, an independent market researcher with a focus on small-cap stocks, released his in-depth analysis on Bioniche today on Seeking Alpha.

Lahiri explains in his analysis that Bioniche is valued at only $25 million; whereas, peer companies are valued well above $100 million. He does suggest that this could change soon, however, with the FDA granting the biopharmaceutical firm permission to file for market approval on its bladder cancer treatment although they haven't completed the Phase III trial yet.

View Lahiri's Report: http://seekingalpha.com/instablog/13833412-sujan-lahiri/3273535-bioniche-a-home-run-buying-opportunity-in-biotech

Bioniche is not only expected to apply for market approval in Q1 2015, but it has already submitted an application to the FDA for Orphan Drug Designation which would give Bioniche 7 years of market exclusivity in the US.

While this company has been well under the radar, Lahiri says, "Odds are Bioniche will obtain an Orphan Drug Designation soon and FDA market approval by next year, enabling them to capture a sizeable market share in the $1 billion addressable bladder cancer market."

With the recent capital raise and balance sheet clean-up, Lahiri says Bioniche has dramatically improved their financials. "This gives them the resources to fund operations for quite a while, enabling management to execute its strategy and it almost assures that they can get their technology through the FDA trials."

This analysis by Lahiri is the first of its kind on Bioniche Life Sciences, which will provide investors an opportunity to learn more about the company and its unique science as it prepares to introduce its bladder treatment to the market.

About Stock Market Media Group

Stock Market Media Group is a research and content development investment relations firm offering a platform for corporate stories to unfold in the media with research reports, CEO interviews and feature articles. For more information: www.stockmarketmediagroup.com.

Contact Information